Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 95
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | ||
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | ||
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | ||
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | ||
| NCT03627403 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | ||
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | ||
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | ||
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | ||
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | ||
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | ||
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | ||
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | ||
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | ||
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | ||
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | ||
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | ||
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | ||
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | ||
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | ||
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | ||
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | ||
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | ||
| NCT05177276 | Selinexor Combination Ph 1 Study | ||
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | ||
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | ||
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | ||
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | ||
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | ||
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | ||
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | ||
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | ||
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | ||
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | ||
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes |
